Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support

Objectives: Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) used as primary prophylaxis in patients receiving myelosuppressive chemotherapy regimens that have greater than 20% risk of developing febrile neutropenia (FN). Historically, pegfilgrastim has been administered 24 to 72 hou...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hosp Pharm
Glavni autori: Patel, Jolly, Rainess, Rebecca Ann, Benfield, Miranda J., Rogers, Kate M. L., Moore, Donald C., Larck, Chris, Arnall, Justin R.
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2019
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958366/
https://ncbi.nlm.nih.gov/pubmed/33790481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0018578719867659
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items